Saniona SANION.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker SANION.ST. It has been listed since 22 April 2014. In the fiscal year to 31 December 2025, it reported revenue of SEK 434.4m and net income of SEK 284.7m. At that date it held total assets of SEK 679.7m and shareholders' equity of SEK 635.2m.

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. John HaurumIndependent Chairman of the BoardSEK 117,000
• Mr. Thomas FeldthusChief Executive Officer, since 2014SEK 4.3m
• Dr. Jorgen DrejerIndependent Deputy Chairman of the Board, since 2014SEK 350,000
• Mr. Johnny StilouChief Financial Officer
• Mr. Janus LarsenChief Operating Officer
• Ms. Karin NielsenChief Scientific Officer
• Dr. Pierandrea MugliaChief Medical Officer, since 2023SEK 200,000
• Ms. Anna LjungIndependent DirectorSEK 434,000
• Prof. Carl SundbergIndependent DirectorSEK 368,000

Overall

43

Environment

49

Social

27

Governance

53

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.